You are here: Home » PTI Stories » National » News
Business Standard

AstraZeneca gets 6-mth extension to sell Meronem in India

Press Trust of India  |  New Delhi 

has got an extension from its parent firm AstraZeneca to sell anti-bacterial drug Meronem in for the next six months.

"Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a filing.

It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem."

Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

In August this year, had said that it will stop selling anti-bacterial drug Meronem in following a global deal by its parent AstraZeneca to sell its small molecule antibiotics business to Inc.

The company had received a notice of termination from AstraZeneca conveying its decision for termination of distribution arrangements for Meronem in

The product is currently one of the company's principal products which generated 18 per cent total turnover of the firm in fiscal ended March 31, 2016.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, December 01 2016. 22:07 IST